title: Hyperacute corticosteroid treatment of optic neuritis at the onset of pain may prevent visual loss: a case series.
abstract: Aim. To show that high-dose corticosteroids may prevent visual loss in patients with optic neuritis (ON) treated at the prodromal, hyperacute, phase of retrobulbar pain. Method. Prospective case series: patients were recruited with a history of ON associated with pain. The patients were advised to report immediately to the investigators should the pain recur in either eye. Where possible, orbital magnetic resonance imaging (MRI) was performed to confirm a recurrence of ON and treatment with high-dose corticosteroids was commenced. Visual function and the patient's subjective account were monitored. Results. Eight patients (including cases of MS, CRION and NMO) presented in the hyperacute phase. MRI confirmed optic nerve inflammation in 5/5. Treatment was commenced immediately, and, in all cases, no visual loss ensued. Conclusion. MRI can be used to confirm acute optic neuritis prior to visual loss in the hyperacute phase. We suggest that treatment with high-dose corticosteroids may abort the attack and prevent loss of vision in patients with ON who are treated at the onset of pain. This has potential implications for the management of acute ON and also for our understanding of the pathogenesis and potential therapeutic targets in the neuroinflammatory conditions associated with ON.
authors.affiliation: Department of Neuro-Ophthalmology, The National Hospital for Neurology and Neurosurgery, London WC1N 3BG, UK.
authors.forename: G T
authors.initials: GT
authors.lastname: Plant
authors.forename: N A
authors.initials: NA
authors.lastname: Sibtain
authors.forename: D
authors.initials: D
authors.lastname: Thomas
references.citation: J Neurol Neurosurg Psychiatry. 2010 Jan;81(1):109-11
references.pmid: 20019228
references.citation: Arch Ophthalmol. 1991 Dec;109(12):1673-8
references.pmid: 1841573
references.citation: Ophthalmology. 2003 Aug;110(8):1646-9
references.pmid: 12917187
references.citation: Lancet. 2004 Dec 11-17;364(9451):2106-12
references.pmid: 15589308
references.citation: Neurology. 1998 Jan;50(1):230-7
references.pmid: 9443485
references.citation: Curr Neurol Neurosci Rep. 2007 May;7(3):259-64
references.pmid: 17488593
references.citation: Brain. 2003 Feb;126(Pt 2):276-84
references.pmid: 12538397
references.citation: Neurol Sci. 2005 May;26 Suppl 2:s75-8
references.pmid: 15926026
references.citation: Brain. 2004 Nov;127(Pt 11):2498-505
references.pmid: 15342363
references.citation: Arch Neurol. 1991 Jul;48(7):748-9
references.pmid: 1859303
references.citation: Cochrane Database Syst Rev. 2007 Jan 24;(1):CD001430
references.pmid: 17253459
references.citation: Semin Ophthalmol. 1995 Sep;10(3):214-20
references.pmid: 10159746
references.citation: Am J Ophthalmol. 2004 Jan;137(1):77-83
references.pmid: 14700647
references.citation: Ophthalmology. 1999 Nov;106(11):2047-53
references.pmid: 10571336
references.citation: Neurol Sci. 2004 Oct;25 Suppl 3:S296-7
references.pmid: 15549567